CHO-K1 cells

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

By Targets:	5-HT Receptor (3) Amino Acid Derivatives (1) Apelin Receptor (APJ) (1) Apoptosis (2) c-Myc (1) EGFR (1) Endogenous Metabolite (1) ERK (1) GCGR (2) GLP Receptor (2) GPR119 (1) Histamine Receptor (1) Histone Acetyltransferase (1) Insulin Receptor (1) Interleukin Related (1) Lipoxygenase (1) PD-1/PD-L1 (1) Prostaglandin Receptor (1) Sodium Channel (1) TGF-beta/Smad (1) Vasopressin Receptor (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Inflammation/Immunology (3) Metabolic Disease (6) Neurological Disease (2)
Click Chemistry:	Azide (1)

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99870

Eblasakimab ASLAN004; CSL-334	Interleukin Related	Others
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .

HY-136895

AZ12672857	Prostaglandin Receptor	Cancer
AZ12672857 is an orally active inhibitor of EphB4 (IC₅₀=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC₅₀=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC₅₀=9 nM) .

HY-108003

MM 07

Apelin Receptor (APJ) Cardiovascular Disease

MM 07 is a biased apelin receptor agonist, with a K_D of 300 nM in CHO-K1 cells and a K_D of 172 nM in human heart.
HY-P99888

Pimurutamab

EGFR Others

Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
HY-P990009

Nisevokitug

NIS-793
TGF-beta/Smad Cancer

Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .

MM 07	Apelin Receptor (APJ)	Cardiovascular Disease
MM 07 is a biased apelin receptor agonist, with a K_D of 300 nM in CHO-K1 cells and a K_D of 172 nM in human heart.

Pimurutamab	EGFR	Others
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .

Nisevokitug NIS-793	TGF-beta/Smad	Cancer
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .

HY-P5872

Jingzhaotoxin XI JZTX-XI	Sodium Channel	Neurological Disease
Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC₅₀ of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC₅₀=1.18±0.2 μM) of Na_v1.5 expressed in Chinese hamster ovary (CHO-K1) cells .

HY-117617

CAY10669	Histone Acetyltransferase	Cancer
CAY10669 (compound 6d) is an anacardic acid (HY-N2020) derivative that inhibits histone acetyltransferase PCAF with an IC₅₀ of 662 μM . CAY10669 enhances the SAHA-induced acetylation in HEPG2 cells, exhibits cytotoxicity in zebrafish embryo, promotes transgene expression in CHO-K1 cells .

HY-161247

5-HT2A antagonist 2	5-HT Receptor	Metabolic Disease
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT_2A with IC₅₀ of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-132225

SB 206553	5-HT Receptor	Inflammation/Immunology
SB 206553 is a 5-HT_2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT_2A), 7.7 nM (5-HT_2B) and 7.8 nM (5-HT_2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders .

HY-103120

Org37684	5-HT Receptor	Neurological Disease
Org37684 is a highly potent 5-HT_2C receptor agonist (pEC₅₀=8.17). Org37684 exhibits a rank order of potency of 5-HT_2C>5-HT_2B>5-HT_2A. Its selectivity for the 5-HT2C receptor is approximately 2.5 times over the 5-HT2B (pEC₅₀=7.96) and ten times for the 5-HT_2A (pEC₅₀=7.11) receptor .

HY-112469

ERK Inhibitor II (Negative control)	ERK Insulin Receptor	Metabolic Disease
ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes .

HY-155553

GPR119 agonist 2	GPR119	Metabolic Disease
GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes .

HY-19443

UCB-35440	Histamine Receptor Lipoxygenase	Inflammation/Immunology
UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation .

HY-162356

PD-L1-IN-4	PD-1/PD-L1	Cancer
PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer .

HY-P1185

Antagonist G	Vasopressin Receptor Apoptosis	Cancer
Antagonist G is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .

HY-P1185A

Antagonist G TFA	Vasopressin Receptor Apoptosis	Cancer
Antagonist G TFA is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .

HY-P2385

Fmoc-Val-Ser(psi(Me,Me)pro)-OH

Amino Acid Derivatives Others

Fmoc-Val-Ser(psi(Me,Me)pro)-OH is a dipeptide.

Fmoc-Val-Ser(psi(Me,Me)pro)-OH	Amino Acid Derivatives	Others
Fmoc-Val-Ser(psi(Me,Me)pro)-OH is a dipeptide.

HY-151884

FUBP1-IN-2	c-Myc	Cancer
FUBP1-IN-2 (compound 9) is a potent FUBP1 (far upstream binding protein 1) inhibitor. FUBP1-IN-2 inhibits the KH4 FUBP1-FUSE interaction in a gel shift assay. FUBP1-IN-2 binds to FUBP1 in a ChIP assay. FUBP1-IN-2 reduces both c-Myc mRNA and protein expression, increases p21 mRNA and protein expression, and depletes intracellular polyamines .

HY-W020790

Sialyl-Lewis X sLeX	Endogenous Metabolite	Inflammation/Immunology
Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) . Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .

Cat. No.	Product Name	Target	Research Area

HY-108003

MM 07

Apelin Receptor (APJ) Cardiovascular Disease

MM 07 is a biased apelin receptor agonist, with a K_D of 300 nM in CHO-K1 cells and a K_D of 172 nM in human heart.

MM 07	Apelin Receptor (APJ)	Cardiovascular Disease
MM 07 is a biased apelin receptor agonist, with a K_D of 300 nM in CHO-K1 cells and a K_D of 172 nM in human heart.

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P3789

Prolactin-Releasing Peptide (12-31), rat	Peptides	Metabolic Disease
Prolactin-Releasing Peptide (12-31), rat is a fragment of the prolactin releasing peptide (PrRP). Prolactin-Releasing Peptide (12-31), rat shows high affinity for GPR10 receptors. Prolactin-Releasing Peptide (12-31), stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor .

HY-P5872

Jingzhaotoxin XI JZTX-XI	Sodium Channel	Neurological Disease
Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC₅₀ of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC₅₀=1.18±0.2 μM) of Na_v1.5 expressed in Chinese hamster ovary (CHO-K1) cells .

HY-P1185

Antagonist G	Vasopressin Receptor Apoptosis	Cancer
Antagonist G is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .

HY-P1185A

Antagonist G TFA	Vasopressin Receptor Apoptosis	Cancer
Antagonist G TFA is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy .

HY-P2385

Fmoc-Val-Ser(psi(Me,Me)pro)-OH

Amino Acid Derivatives Others

Fmoc-Val-Ser(psi(Me,Me)pro)-OH is a dipeptide.

Fmoc-Val-Ser(psi(Me,Me)pro)-OH	Amino Acid Derivatives	Others
Fmoc-Val-Ser(psi(Me,Me)pro)-OH is a dipeptide.

Cat. No.	Product Name

HY-K2014

PEI Transfection Reagent 3 Publications Verification
MCE PEI Transfection Reagent is designed based on 25 kDa PEI. It has high-efficiency, low-toxicity, strong-stability, and is suitable for many cell types, such as HEK-293、HEK-293T、CHO-K1、COS-1、COS-7、NIH/3T3、Sf9、HepG2 and HeLa et, even some hard-to-transfect cells. It can also be applied to large-scale recombinant protein expression and virus production.

Cat. No.	Product Name	Target	Research Area

HY-P99870

Eblasakimab ASLAN004; CSL-334	Interleukin Related	Others
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .

HY-P99888

Pimurutamab

EGFR Others

Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
HY-P990009

Nisevokitug

NIS-793
TGF-beta/Smad Cancer

Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .

Pimurutamab	EGFR	Others
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .

Nisevokitug NIS-793	TGF-beta/Smad	Cancer
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W020790

Sialyl-Lewis X sLeX	Structural Classification Polysaccharides Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite
Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) . Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .

Cat. No.	Product Name		Classification

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Click Chemistry

CHO-K1 cells

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Natural
Products